Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 36,952
  • Shares Outstanding, K 22,810
  • Annual Sales, $ 14,660 K
  • Annual Income, $ 6,970 K
  • 36-Month Beta 3.00
  • Price/Sales 1.85
  • Price/Cash Flow N/A
  • Price/Book 0.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.77
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/15/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.11 +48.65%
on 12/31/18
1.98 -16.67%
on 12/17/18
-0.30 (-15.38%)
since 12/14/18
3-Month
1.11 +48.65%
on 12/31/18
4.45 -62.92%
on 10/16/18
-2.66 (-61.72%)
since 10/15/18
52-Week
1.11 +48.65%
on 12/31/18
6.35 -74.02%
on 05/17/18
-2.75 (-62.50%)
since 01/12/18

Most Recent Stories

More News
Aptevo Therapeutics Highlights Key 2019 Priorities

ADAPTIR(TM) Bispecific Antibody Candidates Poised to Progress in Clinical Development

APVO : 1.65 (+1.85%)
Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has collected $3.3 million in escrow funds from...

APVO : 1.65 (+1.85%)
Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital

Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement

APVO : 1.65 (+1.85%)
Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436

Preclinical Data for APVO436 Show Potential Best-in-Class Attributes with Potent T-Cell Directed Tumor Killing and Reduced Cytokine Production Compared to a Competitor Construct

APVO : 1.65 (+1.85%)
United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercer International Inc. (NASDAQ:MERC),...

SCND : 3.7000 (-0.27%)
ESIO : 29.96 (+0.10%)
EIGI : 7.25 (-0.55%)
APVO : 1.65 (+1.85%)
IDRA : 2.90 (-5.23%)
UPS : 97.56 (-1.59%)
MERC : 11.73 (+1.91%)
Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30 Annual Piper...

APVO : 1.65 (+1.85%)
Aptevo Therapeutics Reports Third Quarter 2018 Financial Results

Achieves 132% Increase in IXINITY Quarterly Net Revenue Year-Over-Year

APVO : 1.65 (+1.85%)
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, and Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology...

APVO : 1.65 (+1.85%)
Aptevo Therapeutics Announces Expanded Growth Initiatives for IXINITY

Plans to Introduce 3000 IU IXINITY Assay for Enhanced Patient Convenience

APVO : 1.65 (+1.85%)
Market Trends Toward New Normal in Aptevo Therapeutics, Bottomline Technologies, Allete, Air Lease, The Goodyear Tire & Rubber, and EastGroup Properties -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Aptevo Therapeutics Inc....

EPAY : 48.60 (+2.55%)
APVO : 1.65 (+1.85%)
ALE : 74.37 (+1.65%)
AL : 36.37 (+0.80%)
GT : 19.00 (-13.04%)
EGP : 95.45 (+1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar